217 related articles for article (PubMed ID: 31821850)
1. The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.
Buchalski B; Wood KD; Challa A; Fargue S; Holmes RP; Lowther WT; Knight J
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165633. PubMed ID: 31821850
[TBL] [Abstract][Full Text] [Related]
2. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.
Li X; Knight J; Fargue S; Buchalski B; Guan Z; Inscho EW; Liebow A; Fitzgerald K; Querbes W; Todd Lowther W; Holmes RP
Biochim Biophys Acta; 2016 Feb; 1862(2):233-9. PubMed ID: 26655602
[TBL] [Abstract][Full Text] [Related]
3. Hydroxyproline metabolism in mouse models of primary hyperoxaluria.
Knight J; Holmes RP; Cramer SD; Takayama T; Salido E
Am J Physiol Renal Physiol; 2012 Mar; 302(6):F688-93. PubMed ID: 22189945
[TBL] [Abstract][Full Text] [Related]
4. Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluria.
Summitt CB; Johnson LC; Jönsson TJ; Parsonage D; Holmes RP; Lowther WT
Biochem J; 2015 Mar; 466(2):273-81. PubMed ID: 25697095
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria.
Fargue S; Milliner DS; Knight J; Olson JB; Lowther WT; Holmes RP
J Am Soc Nephrol; 2018 Jun; 29(6):1615-1623. PubMed ID: 29588429
[No Abstract] [Full Text] [Related]
6. Hydroxyproline ingestion and urinary oxalate and glycolate excretion.
Knight J; Jiang J; Assimos DG; Holmes RP
Kidney Int; 2006 Dec; 70(11):1929-34. PubMed ID: 17021603
[TBL] [Abstract][Full Text] [Related]
7. Effect of alanine supplementation on oxalate synthesis.
Wood KD; Freeman BL; Killian ME; Lai WS; Assimos D; Knight J; Fargue S
Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165981. PubMed ID: 33002578
[TBL] [Abstract][Full Text] [Related]
8. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD
Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyproline-induced hyperoxaluria using acidified and traditional diets in the porcine model.
Kaplon DM; Penniston KL; Darriet C; Crenshaw TD; Nakada SY
J Endourol; 2010 Mar; 24(3):355-9. PubMed ID: 20078233
[TBL] [Abstract][Full Text] [Related]
10. Re: The Effects of the Inactivation of Hydroxyproline Dehydrogenase on Urinary Oxalate and Glycolate Excretion in Mouse Models of Primary Hyperoxaluria.
Assimos DG
J Urol; 2020 May; 203(5):876. PubMed ID: 32073946
[No Abstract] [Full Text] [Related]
11. Development and Validation of a New Gas Chromatography-Tandem Mass Spectrometry Method for the Measurement of Enrichment of Glyoxylate Metabolism Analytes in Hyperoxaluria Patients Using a Stable Isotope Procedure.
van Harskamp D; Garrelfs SF; Oosterveld MJS; Groothoff JW; van Goudoever JB; Schierbeek H
Anal Chem; 2020 Jan; 92(2):1826-1832. PubMed ID: 31867958
[TBL] [Abstract][Full Text] [Related]
12. Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity.
Wood KD; Holmes RP; Erbe D; Liebow A; Fargue S; Knight J
Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2203-2209. PubMed ID: 31055082
[TBL] [Abstract][Full Text] [Related]
13. 4-Hydroxyproline metabolism and glyoxylate production: A target for substrate depletion in primary hyperoxaluria?
Coulter-Mackie MB
Kidney Int; 2006 Dec; 70(11):1891-3. PubMed ID: 17130820
[TBL] [Abstract][Full Text] [Related]
14. Effect of Vitamin B2-Deficient Diet on Hydroxyproline- or Obesity-Induced Hyperoxaluria in Mice.
Uebanso T; Suyama M; Shimohata T; Mawatari K; Takahashi A
Mol Nutr Food Res; 2021 Aug; 65(15):e2100226. PubMed ID: 34110671
[TBL] [Abstract][Full Text] [Related]
15. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J
J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
[TBL] [Abstract][Full Text] [Related]
16. Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria.
Jiang J; Johnson LC; Knight J; Callahan MF; Riedel TJ; Holmes RP; Lowther WT
Am J Physiol Gastrointest Liver Physiol; 2012 Mar; 302(6):G637-43. PubMed ID: 22207577
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial hydroxyproline metabolism: implications for primary hyperoxaluria.
Knight J; Holmes RP
Am J Nephrol; 2005; 25(2):171-5. PubMed ID: 15849464
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic targeting of HYPDH/PRODH2 with N-propargylglycine offers a Hyperoxaluria treatment opportunity.
Bons J; Tadeo A; Scott GK; Teramayi F; Tanner JJ; Schilling B; Benz CC; Ellerby LM
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166848. PubMed ID: 37586438
[TBL] [Abstract][Full Text] [Related]
19. Endogenous Oxalate Production in Primary Hyperoxaluria Type 1 Patients.
Garrelfs SF; van Harskamp D; Peters-Sengers H; van den Akker CHP; Wanders RJA; Wijburg FA; van Goudoever JB; Groothoff JW; Schierbeek H; Oosterveld MJS
J Am Soc Nephrol; 2021 Dec; 32(12):3175-3186. PubMed ID: 34686543
[TBL] [Abstract][Full Text] [Related]
20. Pyridoxamine lowers oxalate excretion and kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
Scheinman JI; Voziyan PA; Belmont JM; Chetyrkin SV; Kim D; Hudson BG
Urol Res; 2005 Nov; 33(5):368-71. PubMed ID: 16292584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
